Cynthia Monesa Clark

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 7 EPO patents. Top assignees: Aerpio Therapeutics, Inc., The Procter Gamble Company, Warner Chilcott Company, LLC. Active years: 2009-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cynthia Monesa Clark. Retrieved from https://idiyas.com/inventor/cynthia-monesa-clark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 5.0

ph-index = 15

Forward Citations = 576(Granted Patents)

Company Filing History:

11 out of 35

Aerpio Therapeutics, Inc.

patents

2 out of 17,173

The Procter Gamble Company

patents

2 out of 39

Warner Chilcott Company, LLC

patents

4. 1 out of 8

Aerpio Pharmaceuticals, Inc.

patents

Years Active: 2009-2019

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10463650 - Human protein tyrosine phosphatase inhibitors and methods of use (2019-11-05),

2. RE46592 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-30),

3. 9795594 - Human protein tyrosine phosphatase inhibitors and methods of use (2017-10-24),

4. 9284285 - Human protein tyrosine phosphatase inhibitors and methods of use (2016-03-15),

5. 9126958 - Human protein tyrosine phosphatase inhibitors and methods of use (2015-09-08),

6. 8946232 - Human protein tyrosine phosphatase inhibitors and methods of use (2015-02-03),

7. 8895563 - Human protein tyrosine phosphatase inhibitors and methods of use (2014-11-25),

8. 8846685 - Human protein tyrosine phosphatase inhibitors and methods of use (2014-09-30),

9. 8338615 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-12-25),

10. 8329916 - Human protein tyrosine phosphatase inhibitors and method of use (2012-12-11),

11. 8258311 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-09-04),

12. 8188125 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-05-29),

13. 8106078 - Human protein tyrosine phosphatase inhibitors and methods of use (2012-01-31),

14. 7795444 - Human protein tyrosine phosphatase inhibitors and methods of use (2010-09-14),

15. 7622593 - Human protein tyrosine phosphatase inhibitors and methods of use (2009-11-24),

Title: Cynthia Monesa Clark: Innovator in Protein Tyrosine Phosphatase Inhibitors

Introduction

Cynthia Monesa Clark is a prominent inventor based in Concord, MA (US). She has made significant contributions to the field of biochemistry, particularly in the development of human protein tyrosine phosphatase inhibitors. With a total of 16 patents to her name, her work has the potential to impact various medical applications.

Latest Patents

Among her latest patents, Cynthia has focused on compounds that act as human protein tyrosine phosphatase beta (HPTP-β) inhibitors. These compounds are crucial for regulating angiogenesis, which is the formation of new blood vessels. The patents detail compositions that include these inhibitors and methods for their use in regulating angiogenesis, showcasing her innovative approach to addressing complex biological processes.

Career Highlights

Cynthia has worked with notable companies such as Aerpio Therapeutics, Inc. and The Procter & Gamble Company. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research in her field.

Collaborations

Cynthia has collaborated with esteemed colleagues, including Jeffrey Lyle Gray and Kande K D Amarasinghe. These partnerships have further enhanced her research and development efforts, leading to advancements in her area of expertise.

Conclusion

Cynthia Monesa Clark stands out as a leading inventor in the realm of protein tyrosine phosphatase inhibitors. Her innovative work and collaborations continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.